Reuters logo
BRIEF-Nanobiotix completes patient inclusion for phase II/III trial of NBTXR3
October 23, 2017 / 6:18 AM / 2 months ago

BRIEF-Nanobiotix completes patient inclusion for phase II/III trial of NBTXR3

Oct 23 (Reuters) - NANOBIOTIX SA:

* NANOBIOTIX COMPLETES PATIENT INCLUSION FOR PHASE II/III TRIAL OF NBTXR3 IN SOFT TISSUE SARCOMA

* ‍LAST PATIENTS ARE EXPECTED TO START TREATMENT IN TWO TO THREE WEEKS​

* ‍EXPECTS TO PRESENT RESULTS OF ITS PHASE II/III TRIAL IN SOFT TISSUE SARCOMA IN FIRST HALF OF 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below